Tag debug info: client: {"assets":{},"datasets":{},"live":{},"projects":{},"users":{},"observable":{"assets":{},"datasets":{},"live":{},"projects":{},"users":{}}} Now: 1770499205989 Cache Key: cqdTagPageBySlug:recurrent-pericarditis fetchCache[cqdTagPageBySlug:recurrent-pericarditis].expirationTime: falsey fetchCache[cqdTagPageBySlug:recurrent-pericarditis]. seconds remaining: falsey All fetchCache expiration times: -- Key: cqdNotFoundPage, seconds remaining: -141171 -- Key: cqdTagPageBySlug:alzheimer-disease-ad, seconds remaining: -164156 -- Key: cqdPostsByTag:cqd-migrated-tag-2825,3,10, seconds remaining: -164087 -- Key: cqdTagPageBySlug:extended-length-of-stay-llos, seconds remaining: -153743 -- Key: cqdPostsByTag:cqd-migrated-tag-20811,1,10, seconds remaining: -153668 -- Key: cqdTagPageBySlug:central-line-associated-blood-stream-infection-clabsi, seconds remaining: -151784 -- Key: cqdPostsByTag:cqd-migrated-tag-15547,1,10, seconds remaining: -151718 -- Key: cqdTagPageBySlug:medical-innovation-summit, seconds remaining: -150711 -- Key: cqdPostsByTag:cqd-migrated-tag-748,1,10, seconds remaining: -150644 -- Key: cqdTagPageBySlug:end-of-life-care, seconds remaining: -148270 -- Key: cqdPostsByTag:cqd-migrated-tag-10048,1,10, seconds remaining: -148198 -- Key: cqdTagPageBySlug:allison-vidimos, seconds remaining: -147119 -- Key: cqdPostsByTag:cqd-migrated-tag-1401,1,10, seconds remaining: -147046 -- Key: cqdTagPageBySlug:covid-19-vaccine, seconds remaining: -145018 -- Key: cqdPostsByTag:cqd-migrated-tag-22853,2,10, seconds remaining: -144862 -- Key: cqdTagPageBySlug:bartolome-burguera, seconds remaining: -141171 -- Key: cqdPostsByTag:cqd-migrated-tag-3369,1,10, seconds remaining: -141105 conditions: -- false, -- NA, -- NA, -- NA -- false Cache miss for key cqdTagPageBySlug:recurrent-pericarditis - retrieving from Sanity CCCache.dataFetchCount: 16226 Cache cleanup seconds remaining: 30000
Advertisement
Advertisement
Tag: recurrent pericarditis
First prognostic tool of its kind for a challenging, debilitating condition
Targeted IL-1 blockers and CMR techniques allow more-tailored treatment strategies
Phase 3 study may lead to first FDA approval for the indication
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Rendered: Sat Feb 07 2026 21:20:06 GMT+0000 (Coordinated Universal Time)
9500 Euclid Avenue, Cleveland, Ohio 44195 |
800.223.2273 | ©
2026 Cleveland Clinic. All Rights Reserved.